T-BINGEN, GERMANY and BOSTON, MA/ACCESSWIRE / September 29, 2020 / CureVac NV (NASDAQ: CVAC), a clinically staged biopharmaceutical company that presents a new elegance of messenger ribonucleic acid processor (“mNS”), announced that the first player has been dosed in a phase 2a clinical trial of its COVID-19 candidate vaccine, CVnCoV. The dose confirmation study, entitled CV-NCOV-002, is conducted in Peru and Panama and will recruit a total of 690 healthy players into two distinct groups: those over 61 and younger from 18 to 60 years old.
Participants will receive two vaccines at 28-day intervals. Different dose grades, starting with 6 mg, will be studied to verify protection and evaluate the reactogenicity of the vaccine in the elderly. In addition, in a geographical environment with a high occurrence of COVID-19 infection, the fun immune reaction after management of CVnCoV will be evaluated and the protection knowledge base will be expanded to prepare for the initiation of a Phase 2b/3 study. The first complete knowledge for Phase 2a in the elderly is expected to develop later in the fourth quarter of 2020.
The design of the exam was coordinated and approved by the government of physical fitness and ethics committees in Peru and Panama and is based on initial knowledge of protection and immunogenicity from the ongoing CureVac Phase 1 CV-NCOV-001 exam in adult volunteers in good physical condition in Germany and Belgium. With knowledge of the existing Phase 1 and Phase 2a exam, CureVac plans to launch the global Phase 2b / 3 clinical trial involving approximately 30,000 participants in the fourth quarter of 2020.
“The start of the Phase 2a clinical trial in Peru and Panama represents a vital step in our COVID-19 clinical studies program,” dr. Mariola Fotin-Mleczek, Chief Technology Officer, CureVac. ” This trial is designed to further verify the dosage variety of our candidate vaccine and verify that we can provide a tolerable vaccine, also to the elderly, who are at increased risk of experiencing serious COVID-19 effects. “
CureVac began the progression of its mNN-based COVID-19 candidate vaccine in January 2020. After extensive preclynic progression, the company began its phase 1 clinical examination of CVnCoV in June 2020 at clinical examination centers in Germany and Belgium. production capacity at its headquarters in Tubinga and is currently expanding those production functions to enable large-scale manufacturing of CVnCoV and other mNR-based vaccines.
About CureVac
CureVac is a clinical-level global biopharmaceutical company in the box of messenger RNA generation (mRNA) with experience in the progression and optimization of this flexible molecule for medical purposes. The precept of the patented generation of CureVac is the use of mRNA as a carrier of knowledge that human structure must be required to produce its own proteins capable of combating a wide variety of diseases. The company applies its technologies to the progression of prophylactic vaccines, cancer therapies, curative antibodies and the remedy of rare diseases. CureVac is headquartered in Tubingen, Germany, and has locations in Frankfurt and Boston, USA.
For more information, see the Company’s reports and documents filed with the U. S. Securities and Exchange Commission. U. S. (SEC) You can download those documents by visiting EDGAR at the SEC www. sec. gov.
SOURCE: CureVac N. V.